There’s trouble brewing beneath the GLP-1 buzz.

As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in record numbers, providers are warning of a troubling ripple effect: patients sliding back into restrictive eating disorders — and others developing them for the first time.

“I think there should be a button that you have to click saying ‘I am consciously making a choice that could really harm my health,’” Dr. Zoe Ross-Nash , a licensed clinical psychologist, told The Post. “Like on cigarette boxes, it says, ‘This could cause cancer.’ OK, well, this [drug] could cause an eating disorder.”

The solemn warning comes amid growing concern about shrinking celebrities — who may or may not be on GLP1s — and whether they’re stick-thinness may fuel a return to early-200

See Full Page